In his statement in the Upper House of Parliament, Dr. Mansukh Mandaviya stated that the objective with which PMBJP was started, which is, about helping quality generic drugs available to the common man at the most affordable rates at dedicated outlets is a successful mission and this policy should be continued for years to come. 

Under the scheme, till 28th February 2022, about 8,689 Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) have been opened, covering all districts of the country, he added. 

Stressing that the Jan Aushadhi medicines are cheaper by 50-90 percent than the market prices of the branded medicines, Mandaviya said, “During the current financial year (till 28th February 2022), total sales of Rs 814.21 crores has been achieved, which has led to an estimated savings of approximately Rs 4,800 crores to the citizens.” In a written reply to another query, the minister said, “During the two years of COVID-19 pandemic, the PMBJP achieved a sale of Rs 665.83 crores during the financial year 2020-21, which has led to the savings of about Rs 4,000 crores to the citizens as compared to the branded medicines.” The product basket of PMBJP currently comprises 1,616 medicines and 250 surgical items covering all major therapeutic groups such as cardiovascular, anti-cancers, anti-diabetics, anti-infectives, anti-allergic, gastro-intestinal medicines, and nutraceuticals, among others, he said in a response to another query. 

This undertaking of the government of India is to enhance the product pannier of generic medicines and surgical. It is a continuous process based on the feedback of various stakeholders and market demands, he added. 

Responding to another question, Mandaviya said, “The government has set a target to have about 10,500 PMBJKs by March 2025 across the country. The target for the year 2022-23 is to have about 9,300 PMBJKs across the country."